TABLE 4.
Sudachi | Placebo | |||||
---|---|---|---|---|---|---|
Baseline | 12 weeks | p Wilcoxon | Baseline | 12 weeks | p Wilcoxon | |
Markers on glycemic control | ||||||
HbA1c (%) | 5.86 ± 0.70 | 5.84 ± 0.62 | .699 | 5.70 ± 0.36 | 5.67 ± 0.37 | .187 |
Fasting glucose (mg/dl) | 90.9 ± 11.5 | 94.1 ± 8.4 | .384 | 97.5 ± 13.1 | 97.5 ± 10.9 | .709 |
Fasting insulin (uU/ml) | 6.61 ± 1.9 | 7.08 ± 2.0 | .265 | 6.21 ± 3.1 | 7.85 ± 4.3 | .324 |
HOMA IR | 1.48 ± 0.44 | 1.67 ± 0.51 | .438 | 1.54 ± 0.86 | 1.87 ± 0.97 | .349 |
HOMA β | 101.5 ± 54.4 | 84.9 ± 27.6 | .453 | 66.3 ± 34.1 | 88.6 ± 56.8 | .785 |
Lipid profile | ||||||
Triglyceride (mg/dl) | 118.0 ± 34.1 | 133.4 ± 56.7 | .185 | 126.5 ± 39.4 | 134.7 ± 72.4 | .181 |
Total cholesterol (mg/dl) | 214.3 ± 35.9 | 210.3 ± 36.0 | <−0.05 | 242.5 ± 20.5 | 237.04 ± 18.1 | .079 |
HDL cholesterol (mg/dl) | 52.9 ± 14.5 | 52.1 ± 15.8 | .923 | 55.3 ± 10.5 | 54.8 ± 7.0 | .925 |
LDL cholesterol (mg/dl) | 132.8 ± 31.0 | 120.9 ± 30.3 | <.001 | 171.0 ± 8.3 | 166.3 ± 21.5 | .282 |
LDL‐C/HDL‐C | 2.67 ± 0.86 | 2.45 ± 0.75 | <.001 | 3.17 ± 0.51 | 3.10 ± 0.73 | .096 |
Body fat analysis | ||||||
Body fat (%) | 30.6 ± 6.2 | 29.6 ± 6.4 | .089 | 28.9 ± 4.6 | 28.6 ± 4.6 | .903 |
TFA (cm2) | 318.8 ± 60.3 | 309.8 ± 63.1 | <.001 | 313.4 ± 41.3 | 316.3 ± 41.5 | .908 |
SFA (cm2) | 194.7 ± 60.0 | 188.9 ± 57.8 | <.001 | 179.3 ± 41.0 | 182.6 ± 36.6 | .964 |
VFA (cm2) | 124.1 ± 14.5 | 121.0 ± 23.6 | <.001 | 134.1 ± 11.7 | 133.7 ± 24.1 | .884 |
VFA/SFA | 0.68 ± 0.20 | 0.58 ± 0.21 | <.001 | 0.79 ± 0.27 | 0.76 ± 0.26 | .853 |
Waist circumference (cm) | 95.3 ± 4.7 | 94.5 ± 4.8 | .058 | 98.9 ± 7.1 | 98.1 ± 5.4 | .855 |
Blood pressures (BP, mm Hg) | ||||||
Systolic BP | 135.1 ± 15.2 | 140.8 ± 8.3 | .373 | 145.8 ± 25.8 | 142.7 ± 19.9 | .817 |
Diastolic BP | 82.8 ± 10.8 | 85.8 ± 10.7 | .583 | 91.0 ± 13.9 | 88.0 ± 10.1 | .678 |
Hypertension (>140/90 mm Hg) | 2 | 2 | ‐ | 3 | 3 | ‐ |
Heart rate (bpm) | 71.4 ± 8.7 | 70.9 ± 8.9 | .913 | 70.8 ± 11.2 | 69.8 ± 11.5 | .918 |